BIOCAD launched the first biopharmaceutical production of drugs based on monoclonal antibodies

6 September 2013
September, the 6th. Launch of the first industrial building of biopharmaceutical production BIOCAD, JSC.

The plant will be produced drugs based on monoclonal antibodies for treatment of cancer and autoimmune diseases.This building has no analogues in Russia.BIOCAD is a resident of SEZ St. Petersburg since 2010. Construction of the production building has begun in 2011. Its production capacity will reach 160 kg of monoclonal antibodies per year.  The whole BIOCAD project in SEZ involves the construction of 6 objects for production of 32 vital & essential drugs. Three type of drugs from this list (rituximab, trastuzumab, bevacizumab) are approved by the Commission under the President of the Russian Federation on modernization and technological development of Russia and financed from the federal budget in the form of subsidies under the "Strategy of development of the domestic pharmaceutical industry until 2020 (Pharma-2020)".


Head of RUSSEZ Mikhail Trushko:

Pharmaceuticals - is a priority direction of development of St. Petersburg and Russia as a whole, which requires a coherent interaction between government and business. SEZ successfully creates organizational and infrastructural conditions for effective public-private partnership. And the opening of another of new enterprise BIOCAD is a clear confirmation of that.

Managing director of SEZ St. Petersburg Farid Verdiev:

BIOCAD is a second company opened plant in the SEZ.But it's the first pharmaceutical plant for medical drugs producing. BIOCAD products is social-meaning vital medications. They are intended for the treatment of serious diseases. The penetration of these products to our market has a huge importance for our medicine, including, the segment of public procurement of medicines.

 

All news